Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:31:38 EDT Thu 26 Mar 2026
Enter Symbol
or Name
USA
CA



Q:IBIO - IBIO INC - https://www.ibioinc.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
IBIO - Q0.31.74·1.751.01.74-0.44-20.22,317.23,3354,3541.68  1.7499  1.434.74  0.556210:13:00Mar 1615 min RT 2¢

Recent Trades - Last 10 of 4354
Time ETExPriceChangeVolume
10:13:02Q1.745-0.435200
10:13:02Q1.745-0.4351,000
10:13:02Q1.745-0.435100
10:13:02Q1.74-0.44100
10:13:00Q1.7437-0.436340
10:12:56Q1.7411-0.4389500
10:12:56Q1.74-0.44100
10:12:51Q1.7498-0.4302100
10:12:51Q1.7498-0.4302400
10:12:47Q1.7498-0.4302100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-03-16 16:30U:IBIONews ReleaseiBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
2026-03-09 07:00U:IBIONews ReleaseiBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss
2026-02-24 07:00U:IBIONews ReleaseiBio to Participate in Upcoming Investor Conferences
2026-02-10 16:05U:IBIONews ReleaseiBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-01-09 07:00U:IBIONews ReleaseiBio Announces $26 Million Private Placement
2025-11-24 16:15U:IBIONews ReleaseiBio to Participate in the 8th Annual Evercore Healthcare Conference
2025-11-12 16:01U:IBIONews ReleaseiBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update
2025-10-30 07:00U:IBIONews ReleaseiBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance
2025-10-23 07:00U:IBIONews ReleaseiBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
2025-10-21 07:00U:IBIONews ReleaseiBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek(TM) and PEGS Europe 2025
2025-09-05 07:30U:IBIONews ReleaseiBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
2025-08-25 07:00U:IBIONews ReleaseiBio Announces Closing of $50 Million Public Offering
2025-08-19 08:01U:IBIONews ReleaseiBio Announces Pricing of $50 Million Public Offering
2025-08-18 16:01U:IBIONews ReleaseiBio Announces Proposed Public Offering
2025-06-24 07:00U:IBIONews ReleaseiBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results
2025-06-23 16:15U:IBIONews ReleaseiBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call
2025-06-16 07:00U:IBIONews ReleaseiBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment
2025-05-05 08:00U:IBIONews ReleaseiBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model
2025-05-02 08:00U:IBIONews ReleaseiBio Reports Fiscal Third Quarter 2025 Financial Results
2025-04-29 13:44U:IBIONews ReleaseiBio Raises $6.2 Million Through Warrant Inducement Transaction